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Abstract
Introduction: B cell-activating factor of the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand
(APRIL) play a crucial role in B cell development, survival, and antibody production. Here we analyzed the serum
levels of BAFF and APRIL and their respective clinical associations in patients with an immunoglobulin (Ig) G4-
related disease (IgG4-RD).
Methods: We measured serum levels of BAFF and APRIL in patients with IgG4-RD, primary Sjögren’s syndrome
(pSS), and healthy individuals. Serum BAFF and APRIL levels in IgG4-RD were assessed for correlations with
serological parameters, including Ig, particularly IgG4, and the number of affected organs. Serum BAFF and APRIL
levels in IgG4-RD were monitored during glucocorticoid (GC) therapy.
Results: Serum BAFF and APRIL levels in patients with IgG4-RD were significantly higher (P < 0.01) than in healthy
individuals. The BAFF levels of patients with IgG4-RD were comparable to those of patients with pSS. Although
clinical parameters, such as serum IgG4 and the number of affected organs, were not correlated with the levels of
BAFF, serum APRIL levels were inversely correlated with serum IgG4 levels (r = -0.626, P < 0.05). While serum BAFF
levels decreased following GC therapy, serum APRIL levels increased during follow-up.
Conclusion: These results indicate that BAFF and APRIL might be useful markers for predicting disease activity in
IgG4-RD. Further studies are needed to elucidate the role of BAFF and APRIL in the pathogenesis of IgG4-RD.
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a
multi-organ disorder characterized by hyper-IgG4 g-glo-
bulinemia, organ infiltration of IgG4-bearing plasma
cells, and tissue sclerosis [1-3]. IgG4-RD has recently
been recognized as a distinct clinical entity [1-4] com-
prising a number of disorders, such as type 1 autoim-
mune pancreatitis (AIP) [3,5-7], sclerosing cholangitis
[8], Mikulicz’s disease (MD) [1], Küttner’s tumor [9],
Riedel thyroiditis [10], inflammatory aneurysm [11],
tubulointerstitial nephritis [12], and retroperitoneal
fibrosis [13,14]. Because the cause of IgG4-RD is
unknown, it remains unclear whether this disease should
be classified as autoimmune, allergic, or hematologic.
Hypergammaglobulinemia and the existence of dis-
ease-related autoantibodies (for example, those against
lactoferrin [15], carbonic anhydrase II (CAII) [16], amy-
lase-alpha 2A [17], pancreatic secretory trypsin inhibitor
(PSTI) [18], and plasminogen-binding protein peptide
[19]) support the hypothesis that autoimmunity may
participate in the pathogenesis of IgG4-RD. While the
mechanism by which B cells preferentially skew IgG4-
class switching is still not determined, recent studies
with affected tissue [20,21] have suggested that T helper
2 (Th2) phenotypes of CD4+T cells and regulatory T
cells play a crucial role in excessive production of IgG4
and tissue fibrosis.
B cell-activating factor of the tumor necrosis factor
(TNF) family (BAFF, also known as B-lymphocyte sti-
mulator (BLyS) or TNF and apoptosis leukocyte-
expressed ligand-1 (TALL-1)) and its homolog, a prolif-
eration-inducing ligand (APRIL, also known as TNF-
related death ligand 1 (TRDL-1) or TNF and apoptosis
leukocyte-expressed ligand-2 (TALL-2), are members of
the trimeric TNF family, and both play an essential role
in the homeostasis of peripheral B cells [22]. Both
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cytokines are known to be expressed by a variety of cell
types, particularly the myeloid-lineage cells [22,23].
BAFF is synthesized as a membrane-bound or secreted
protein, while APRIL exists solely in the secreted form
[24]. BAFF binds to three receptors - BAFF receptor
(BAFF-R), transmembrane activator and calcium-modu-
lating cyclophilin ligand interactor (TACI), and B cell
maturation antigen (BCMA) - which are expressed by B
cells, whereas APRIL binds to TACI and BCMA [25].
BAFF and APRIL are thought to mediate the regula-
tion of B cell maturation, survival, CD40L-independent
antibody production, and isotype switching through
BAFF-R and TACI [22,23,26,27]. Because overexpression
of BAFF is known to induce B cell hyperactivation and
autoimmunity in mice [28], BAFF has been considered a
promoting factor in the pathogenesis of several autoim-
mune and allergic diseases. In fact, elevated serum levels
of BAFF were observed in patients with rheumatoid
arthritis (RA) [29], systemic lupus erythematosus (SLE)
[30], primary Sjögren’s syndrome (pSS) [31,32], inflam-
matory myositis (IM) [33], systemic sclerosis (SSc) [34],
bronchial asthma [35], and atopic dermatitis [36], and
serum BAFF levels were associated with their clinical
activity. In contrast, overexpression of APRIL has not
been associated with autoimmunity in mice but leads to
enhanced IgM production, T cell-independent type 2
humoral responses, and T cell proliferation [37]. On the
other hand, a lack of APRIL is associated with an
increased percentage of CD44hiCD62Llow effector mem-
ory T cells and impaired class switching to IgA [38,39].
Although APRIL has been found to be elevated in
patients with autoimmune diseases, including SLE [40],
pSS [32], and multiple sclerosis [41], it is still under
debate whether APRIL has a role in human autoimmu-
nity, and its circulating levels do not parallel those of
BAFF.
The aim of this study was to investigate the contribu-
tion of BAFF and APRIL in the pathogenesis of IgG4-
RD. We assessed serum levels of BAFF and APRIL by
ELISA to analyze their association with clinical manifes-
tations, serological parameters, and treatment.
Materials and methods
Patients
All patients were recruited from the Department of
Rheumatology and Clinical Immunology, Kyoto Univer-
sity Hospital, Kyoto, Japan. Patients with IgG4-RD (n =
18; 5 females, 13 males; mean age, 68.6 ± 12.3 years;
range, 37 to 79 years) were included in the study.
Patients were diagnosed on the basis of clinicopatholo-
gic findings [3,4], clinical findings (diffuse/focal enlarge-
ment or mass formation, nodular/thickened lesions in
one or more organs), elevated serum IgG4 (> 135 mg/
dL), and histopathologic features including infiltration of
lymphocytes and IgG4-positive (+) plasma cells (IgG4
+plasma cells/IgG+plasma cells > 40% and/or IgG4+
plasma cells > 10 cells in 5 high-power fields) with typi-
cal tissue fibrosis or sclerosis. None of the patients met
the criteria for sarcoidosis, Castleman’s disease, Wege-
ner granulomatosis, malignant lymphoma, or pSS.
Serum samples were obtained before (n = 13) and after
(n = 5) glucocorticoid (GC) treatment, and the serum
from six patients before GC treatment was drawn
repeatedly during GC treatment. Ten healthy individuals
and thirteen individuals with pSS were enrolled and
served as healthy and disease controls, respectively. All
of the patients with pSS had signs and symptoms that
satisfied the Japanese Ministry of Health criteria for the
diagnosis of pSS. All patients and healthy volunteers
provided informed consent in accordance with the
Declaration of Helsinki, before providing samples. This
study was approved by the Medical Ethics Committee of
Kyoto University Graduate School of Medicine.
Measurement of serum levels of BAFF and APRIL
Serum levels of BAFF were determined using an
enzyme-linked immunosorbent assay (ELISA) kit (R&D
Systems, Minneapolis, MN, USA), and serum levels of
APRIL were determined using an ELISA kit (BioVendor
Laboratory Medicine, Modrice, Czech Republic). All
serum samples were stored at -20°C until use.
Statistical analysis
Statistical analysis was performed with GraphPad Prism
version 5.0a software (GraphPad Software, Inc., San
Diego, CA, USA). Nonparametric tests were performed
using the Mann-Whitney U test for comparison of the
two groups. Correlations were determined by Spear-
man’s correlation. A value of P < 0.05 was considered
statistically significant. Data are shown as mean ± stan-
dard definition (SD).
Results
Clinical, laboratory, and histological features of
immunoglobulin G4-related disease (IgG4-RD)
We measured serum levels of BAFF and APRIL in 18
patients with IgG4-RD before GC therapy (cases 1 to
13) and after GC therapy (cases 14 to 18) (Table 1). The
duration of GC treatment ranged from five days to thir-
teen years in five patients (cases 14 to 18). Twelve of
eighteen (66.7%) patients with IgG4-RD were elderly
men. Serum IgG4 levels were > 135 mg/dL in all
patients. Biopsy specimens from affected tissues were
obtained from 15 of 18 patients, and abundant IgG4-
bearing plasma cell infiltration with lymphoplasmacytic
infiltrates and sclerosis was observed in all patients.
Three patients (cases 7, 14, and 17), who did not agree
to undergo biopsy had their conditions diagnosed as
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IgG4-RD on the basis of hyper-IgG4 g-globulinemia and
typical clinical findings after other diseases were ruled
out. Test results of four patients (cases 4, 6, 12, and 18)
were positive for rheumatoid factor (RF), those of 10
patients (cases 1 to 5, 9, 12, 14, 16, and 18) were posi-
tive for antinuclear antibody (ANA), and those of two
patients (cases 3 and 16) were positive for anti-SS-A
antibody. Retroperitoneal fibrosis (RPF) was the most
frequent clinical manifestation in our cohort.
Increased serum BAFF and APRIL in IgG4-RD
As shown in Figure 1a, serum levels of BAFF in patients
with IgG4-RD before GC therapy (n = 13, 1.512 ± 0.393
ng/mL) were significantly higher than those in healthy
controls (n = 10, 0.904 ± 0.262 ng/mL) (P < 0.01), and
there were no significant differences in the serum levels
of BAFF between patients with IgG4-RD before GC
therapy and patients with pSS (n = 13, 1.820 ± 0.954
ng/mL) (P = 0.383). Serum levels of BAFF in patients
with IgG4-RD after GC therapy (n = 5, 0.749 ± 0.283
ng/mL) were lower than in those before GC therapy (P
< 0.01). In contrast, as shown in Figure 1b, serum levels
of APRIL in patients with IgG4-RD before GC therapy
(n = 13, 3.736 ± 3.271 ng/mL) were significantly higher
than those in the healthy controls (n = 10, 1.327 ±
1.259 ng/mL) (P < 0.01), however, unlike BAFF, the
levels were significantly lower than those in patients
with pSS (n = 13, 11.250 ± 7.418 ng/mL) (P < 0.01).
Inverse correlation between serum APRIL and IgG4 in
patients with IgG4-RD
While no significant correlation was found between
serum levels of BAFF and IgG4 in patients with IgG4-
RD before GC therapy (n = 13, r = -0.159, P = 0.603)
(Figure 2a), a significant inverse correlation was found
for APRIL before GC therapy (n = 13, r = -0.626, P =
0.022) (Figure 2b).
No correlation between number of affected organs and
serum BAFF or APRIL in patients with IgG4-RD
To assess the association between serum BAFF/APRIL
and disease severity, we counted the number of affected
organs from a list of 10 organs (lacrimal glands, salivary
glands, lung, pancreas, kidney, retroperitoneum, lymph
node, thyroid glands, prostate, and orbit), which are
known to be involved in IgG4-RD. As shown in Figure
3a, a significant correlation between the number of
affected organs and serum levels of IgG4 was found in
patients with IgG4-RD (n = 18, r = 0.638, P = 0.004).
However, as shown in Figure 3b and 3c, no significant
correlation was found between the number of affected
organs and serum levels of BAFF (n = 13, r = -0.307, P
Table 1 Clinical characteristics of patients with immunoglobulin G4-related disease (IgG4-RD).
Case Age Serum IgG4
(mg/dL)
RF ANA Clinical manifestation Biopsy/IgG4/IgG ratio
1 73 2890 < 6 40 Lymph, Mikulicz’s disease
Prostatitis
Prostate/0.60
2 76 2210 < 6 40 Mikulicz’s, RPF Submandibular gland/0.40
3 79 1460 < 6 160
(SS-A)
IN, IP, Küttner’s tumor, Lymph, RPF Submandibular gland/0.73
4 66 1090 30.3 40 AIP, IN, Renal pseudotumor Kidney/0.70
5 73 592 < 6 320 IN, IP, Lymph, RPF, Sialadenitis Submandibular gland/0.43
6 62 736 52.0 < 40 Sialadenitis, Lymph Parotid gland/0.30*
7 77 738 < 6 < 40 Mikulicz’s disease ND.
8 74 389 < 6 < 40 Retro-orbital tumor Retro-orbital tumor/0.48
9 76 760 < 6 40 AIP, Periureteritis Ureter/0.38
10 52 383 < 6 < 40 Küttner’s tumor Submandibular gland/0.57
11 70 724 < 6 < 40 Küttner’s tumor, Lymph Submandibular gland/0.40
12 46 675 26.8 80 Mikulicz’s disease Lachrymal gland/0.41
13 37 533 < 6 < 40 Mikulicz’s disease Lachrymal gland/0.50
14 77 655 < 6 80 RPF ND
15 76 458 < 6 < 40 AIP, RPF Retroperitoneal/0.70
16 62 315 < 6 40
(SS-A)
AIP, RPF Pancreas/0.43
17 79 309 ND < 40 RPF ND
18 79 1960 65 40 Orbital tumor, Lymph, Lung nodule Orbital tumor/0.59
AIP, autoimmune pancreatitis; ANA, antinuclear antibody; IN, interstitial nephritis; IP, interstitial pneumonia; Lymph, lymphadenopathy; ND, not determined; RF,
rheumatoid factor; RPF, retroperitoneal fibrosis; SS-A, anti-SS-A antibody; *, IgG4-positive plasmacytes > 100/high-power fields.
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Figure 1 Serum levels of BAFF and APRIL in IgG4-RD. (a) Serum levels of BAFF in patients with IgG4-RD before (G4 pre Tx) and after (G4
post Tx) treatment with glucocorticoids (GC). (b) Serum levels of APRIL in patients with IgG4-RD before (G4 pre Tx) and after (G4 post Tx)
treatment with GC. Mean ± Standard deviation (SD) are shown. *, P < 0.01. HC, healthy controls; SS, patients with Sjögren syndrome; Tx,
treatment.
Figure 2 Correlation between serum BAFF or APRIL and serum IgG4 in patients with IgG4-RD. Correlation between serum levels of BAFF
(a) or APRIL (b) and IgG4 in patients with IgG4-RD.
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= 0.307) or APRIL (n = 13, r = -0.371, P = 0.212) in
patients with IgG4-RD before GC therapy.
Changes in serum BAFF and APRIL in patients with IgG4-
RD during GC therapy
Six patients with IgG4-RD were treated with oral pre-
dnisolone (0.6 mg/kg/day) for two weeks, tapering there-
after by 10% of the dose every two weeks, and serum
samples were drawn repeatedly to monitor serum BAFF
and APRIL during treatment (Figure 4). After treatment,
serum levels of BAFF dramatically declined to levels
observed in healthy controls in most cases; however, the
levels increased again during follow-up (Figure 4a). In
contrast, serum levels of APRIL did not decrease during
treatment and increased markedly after treatment in
most cases (Figure 4b).
Discussion
This is the first study to demonstrate both an increase
in BAFF and APRIL levels in patients with IgG4-RD as
well as the differential effects of GC treatment on BAFF
and APRIL in patients with IgG4-RD. Promotion of B
cell activation, plasmacyte differentiation, and germinal
center formation by BAFF and APRIL [42], and ectopic
germinal center formation in lacrimal and salivary
glands from patients with MD [43] suggest that inap-
propriate BAFF and APRIL may contribute to progres-
sive plasmacyte infiltration and ectopic germinal center
Figure 3 Correlation between organ involvement and serum IgG4, BAFF, or APRIL in patients with IgG4-RD. Correlation between the
number of affected organs and IgG4 (a), BAFF (b), and APRIL (c) in patients with IgG4-RD.
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formation in the target organs of patients with IgG4-
RD. In addition, it has been demonstrated that BAFF
and APRIL enhance class switching to produce IgG4
and IgE in the presence of IL-4 [44,45]. Previous stu-
dies have shown that production of Th2 cytokines,
such as IL-4, IL-5, and IL-13 was augmented in the
tissue of patients with AIP [20]. Therefore, increased
expression of both cytokines may contribute to the
pathogenesis of IgG4-RD in concert with cognate Th2
cells. In particular, three (cases 3, 4 and 12) out of
five patients (cases 3, 4, 10, 11 and 12) with high
BAFF levels (> 1.5 ng/mL) had positive test results for
autoantibodies (for example, RF or anti-SS-A anti-
body), which is consistent with previous studies show-
ing that serum BAFF levels were correlated with
positive results for serum autoantibodies in patients
with RA [29], SLE [30], pSS [31], or IM [33]. BAFF
might also play a role in the breakdown of B cell tol-
erance in patients with IgG4-RD. Recently, it has been
reported that serum levels of BAFF were higher in
patients with AIP than in those with pancreatic cancer
or chronic pancreatitis [46]. The same studies also
demonstrated that serum BAFF levels were signifi-
cantly correlated with serum levels of IgG and IgG4
in patients with AIP, which was not observed in our
cohort. The relatively small number of patients in our
study or the enrollment of different subsets of patients
might explain this discrepancy.
Of interest, we found an inverse correlation between
serum APRIL and serum IgG4 levels in patients with
IgG4-RD. In SLE, a similar inverse correlation between
serum APRIL levels and anti-double-stranded DNA
antibody titers has been reported [47], and serum
APRIL was inversely associated with disease activity.
Thus, APRIL might serve as a protective factor against
the progression of IgG4-RD. In our cohort, serum IgG4
levels were significantly correlated with the number of
affected organs, clearly indicating that serum IgG4 levels
reflect disease severity. Although no significant correla-
tion existed between serum BAFF levels and serum
immunoglobulins or the number of affected organs, GC
treatment dramatically reduced serum levels of BAFF as
well as serum IgG4. In patients with AIP, reduced
serum levels of BAFF after 12 weeks of GC treatment
have been reported [46], a result similar to our finding.
Thus, serum BAFF levels might reflect the clinical activ-
ity of this disease. During long-term (up to 26 weeks)
follow-up, we observed that the elevated levels of serum
BAFF reoccurred in most cases; however, no patients
suffered clinical relapse. Further follow-up study will be
needed to clarify the relationship between the reoccur-
rence of elevated serum BAFF and clinical relapse in
IgG4-RD. In contrast to the rapid reduction of BAFF by
GC treatment, serum levels of APRIL increased over the
course of treatment. Similar changes in serum levels of
BAFF and APRIL have been reported in patients with
Figure 4 Changes in serum levels of BAFF and APRIL in patients with IgG4-RD during GC therapy. Serum levels of BAFF (a) and APRIL (b)
were monitored during and after GC therapy (n = 6).
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GC-treated SLE [47]. Furthermore, no significant corre-
lation was observed between serum BAFF levels and
serum APRIL during GC treatment in our patients (data
not shown). Thus, universal but distinct mechanisms
might exist to control the expression of BAFF and
APRIL during GC treatment.
Conclusions
We demonstrate for the first time that serum BAFF and
APRIL levels are increased in patients with IgG4-RD
and that the levels of both are indirectly related to clini-
cal activity. Our findings add to the body of knowledge
on the role of BAFF and APRIL in the pathogenesis of
IgG4-RD. Further longitudinal studies with larger num-
bers of patients are required to determine the role of
the BAFF/APRIL system and to determine whether
BAFF and APRIL might serve as therapeutic targets in
IgG4-RD.
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